Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of S-892216-PO in Participants With Renal Impairment
NCT07217886Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of S-892216 (5 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration and 2 more. Started Oct 2025; status: completed.
02
Drugs
S-892216
Beyond the preview
Go deeper on NCT07217886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217886.